U.S. markets closed
  • S&P 500

    3,818.83
    -2.72 (-0.07%)
     
  • Dow 30

    31,029.31
    +82.32 (+0.27%)
     
  • Nasdaq

    11,177.89
    -3.65 (-0.03%)
     
  • Russell 2000

    1,719.37
    -19.47 (-1.12%)
     
  • Crude Oil

    109.68
    -0.10 (-0.09%)
     
  • Gold

    1,819.70
    +2.20 (+0.12%)
     
  • Silver

    20.72
    -0.02 (-0.09%)
     
  • EUR/USD

    1.0446
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • GBP/USD

    1.2123
    +0.0000 (+0.00%)
     
  • USD/JPY

    136.5770
    +0.0320 (+0.02%)
     
  • BTC-USD

    20,099.65
    -231.90 (-1.14%)
     
  • CMC Crypto 200

    434.46
    -5.20 (-1.18%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.

  • This submission is based on the totality of the data from clinical and preclinical studies, including the results of the Phase 2 portion of the EMPATHY study, which enrolled 407 symptomatic COVID-19 patients.

  • Related: Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data.

  • Ensovibep is a DARPin therapeutic candidate designed specifically to inhibit target cell entry of SARS-CoV-2, the virus that causes COVID-19.

  • DARPin's (Designed Ankyrin Repeat Proteins) are mono or multi-specific protein-based therapies designed to engage their targets for various effects specifically. E

  • Price Action: MOLN shares traded 0.27% higher at $26.19, NVS shares are up 0.72% at $87.83 during the premarket session on the last check Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.